Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2013)
All Articles published online
|
Jul 14, 2007 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Schott E, Paul F, Wuerfel JT, Zipp F, Rudolph B, Wiedenmann B, Baumgart DC. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferonβ 1a. World J Gastroenterol 2007; 13(26): 3638-3640 [PMID: 17659718 DOI: 10.3748/wjg.v13.i26.3638] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i26/3638.htm |
| Number | Citing Articles |
| 1 |
Claudia Pena Rossi, Stephen B Hanauer, Ratko Tomasevic, John O Hunter, Ira Shafran, Hans Graffner. Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study. BMC Gastroenterology 2009; 9(1) doi: 10.1186/1471-230X-9-22
|
| 2 |
Adelle P. McFarland, Ram Savan, Sagie Wagage, Augustina Addison, Karthika Ramakrishnan, Megan Karwan, Tri Duong, Howard A. Young, Jacques Zimmer. Localized Delivery of Interferon-β by Lactobacillus Exacerbates Experimental Colitis. PLoS ONE 2011; 6(2): e16967 doi: 10.1371/journal.pone.0016967
|
| 3 |
S. Rodrigues, F. Magro, J. Soares, A. C.R. Nunes, S. Lopes, M. Marques, E. Rio, G. Macedo. Case Series: Ulcerative Colitis, Multiple Sclerosis, and Interferon-Beta 1a. Inflammatory Bowel Diseases 2010; 16(12): 2001 doi: 10.1002/ibd.21242
|
| 4 |
Rachele Del Sordo, Vassilios Lougaris, Gabrio Bassotti, Alessandro Armuzzi, Vincenzo Villanacci. Therapeutic agents affecting the immune system and drug-induced inflammatory bowel disease (IBD): A review on etiological and pathogenetic aspects. Clinical Immunology 2022; 234: 108916 doi: 10.1016/j.clim.2021.108916
|
| 5 |
Tobias Brummer, Tobias Ruck, Sven G. Meuth, Frauke Zipp, Stefan Bittner. Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders. Therapeutic Advances in Neurological Disorders 2021; 14 doi: 10.1177/17562864211035542
|
| 6 |
Georgia Deretzi, Jannis Kountouras, Evangelos Koutlas, Christos Zavos, Stergios Polyzos, Jobst Rudolf, Nikolaos Grigoriadis, Emmanuel Gavalas, Marina Boziki, Iakovos Tsiptsios. Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Multiple Sclerosis Journal 2010; 16(9): 1091 doi: 10.1177/1352458510375708
|
| 7 |
Takuya Watanabe, Haruka Hirono, Katsuhiko Hasegawa, Kenji Soga, Koichi Shibasaki. Literature review in cases with exacerbation of ulcerative colitis induced by treatment with interferon and/or ribavirin. Journal of Gastroenterology and Hepatology 2011; 26(12): 1709 doi: 10.1111/j.1440-1746.2011.06890.x
|
| 8 |
José M. González-Navajas, Jongdae Lee, Michael David, Eyal Raz. Immunomodulatory functions of type I interferons. Nature Reviews Immunology 2012; 12(2): 125 doi: 10.1038/nri3133
|
| 9 |
Laura Dumitrescu, Cris S. Constantinescu, Radu Tanasescu. Recent developments in interferon-based therapies for multiple sclerosis. Expert Opinion on Biological Therapy 2018; 18(6): 665 doi: 10.1080/14712598.2018.1462793
|
| 10 |
Viviana Nociti, Marina Romozzi. Multiple Sclerosis and Autoimmune Comorbidities. Journal of Personalized Medicine 2022; 12(11): 1828 doi: 10.3390/jpm12111828
|
| 11 |
Eveline D. de Geus, Jennifer S. Volaric, Antony Y. Matthews, Niamh E. Mangan, Janet Chang, Joshua D. Ooi, Nicole A. de Weerd, Edward M. Giles, Paul J. Hertzog. Epithelially Restricted Interferon Epsilon Protects Against Colitis. Cellular and Molecular Gastroenterology and Hepatology 2024; 17(2): 267 doi: 10.1016/j.jcmgh.2023.10.006
|
| 12 |
Sareh Shahmohammadi, Mohammad Ali Sahraian, Abootorab Shahmohammadi, Rozita Doosti, Ali Zare-Mirzaie, Abdorreza Naser Moghadasi. A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. Multiple Sclerosis and Related Disorders 2018; 22: 22 doi: 10.1016/j.msard.2018.02.030
|
| 13 |
Oliver Brain, Simon PL Travis. Therapy of ulcerative colitis: state of the art. Current Opinion in Gastroenterology 2008; 24(4): 469 doi: 10.1097/MOG.0b013e3282ff0dd5
|
| 14 |
Jun-Bao Fan, Sayuri Miyauchi-Ishida, Kei-ichiro Arimoto, Dan Liu, Ming Yan, Chang-Wei Liu, Balázs Győrffy, Dong-Er Zhang. Type I IFN induces protein ISGylation to enhance cytokine expression and augments colonic inflammation. Proceedings of the National Academy of Sciences 2015; 112(46): 14313 doi: 10.1073/pnas.1505690112
|
| 15 |
Oliver Brain, Simon PL Travis. Therapy of ulcerative colitis: state of the art. Current Opinion in Internal Medicine 2008; 7(5): 477 doi: 10.1097/MCI.0b013e3283154e13
|
| 16 |
Zhen Shen, Yan-zhi Huang, Li-min Ning, Hai-cheng Gao, Wei Wang. A case of lower digestive tract hemorrhage caused by appendicitis in China. International Journal of Surgery Case Reports 2017; 39: 34 doi: 10.1016/j.ijscr.2017.06.038
|
| 17 |
Albrecht Neesse, Patrick Michl, Steffen Kunsch, Thomas M. Gress, Martin Steinkamp. Glatiramer acetate: A novel therapeutic approach in Crohnʼs disease?. Inflammatory Bowel Diseases 2009; 15(1): 156 doi: 10.1002/ibd.20537
|
| 18 |
Basilio Vagner Ramirez, Catalina Rojas Acosta. Neuroimmune interaction between multiple sclerosis and inflammatory bowel disease. World Journal of Neuroscience 2013; 3(04): 199 doi: 10.4236/wjns.2013.34025
|
| 19 |
Chen Hsing Lin, S. Kadakia, Marianne Frieri. New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease. Autoimmunity Reviews 2014; 13(2): 114 doi: 10.1016/j.autrev.2013.09.011
|
| 20 |
R. J. Greenstein, T. Gillis, D. S. Scollard, S. T. Brown. Sequelae and Long-Term Consequences of Infectious Diseases. 2014; : 135 doi: 10.1128/9781555815486.ch8
|
| 21 |
Aristeidis H Katsanos, Konstantinos H Katsanos. Inflammatory bowel disease and demyelination: more than just a coincidence?. Expert Review of Clinical Immunology 2014; 10(3): 363 doi: 10.1586/1744666X.2014.885381
|
| 22 |
Sudheer K. Vuyyuru, Sarah A. Morrow, Vipul Jairath. Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone. ACG Case Reports Journal 2023; 10(1): e00955 doi: 10.14309/crj.0000000000000955
|
| 23 |
Yawei Liu, Ingrid Teige, Ida Ericsson, Vaidrius Navikas, Shohreh Issazadeh‐Navikas. Suppression of EAE by oral tolerance is independent of endogenous IFN‐β whereas treatment with recombinant IFN‐β ameliorates EAE. Immunology & Cell Biology 2010; 88(4): 468 doi: 10.1038/icb.2009.111
|
| 24 |
Malte Bachmann, Solongo Ulziibat, Lorena Härdle, Josef Pfeilschifter, Heiko Mühl. IFNα converts IL-22 into a cytokine efficiently activating STAT1 and its downstream targets. Biochemical Pharmacology 2013; 85(3): 396 doi: 10.1016/j.bcp.2012.11.004
|